Patient-Centered Opioid Tapering Study

Background: Background: An estimated 11 million Americans were prescribed long term opioids in 2014—up to 4 percent of the entire U.S. adult population. Patients with chronic pain taking long term opioids are at higher risk for multiple health problems including more severe pain and addiction, and death from accidental overdose. Opioid related overdoses are now a leading cause of death in the U.S. Multiple national agencies have called for reduced opioid prescriptions.

Lower doses of opioids are safer for patients. Patients who take very high dose opioids for chronic pain (>200 morphine equivalent daily dose; MEDD) are at 3-fold increased risk for accidental overdose death compared to those on low doses (1). However, the primary patient concern about reducing opioids is fear of having increased pain. Indeed, evidence is lacking for how to help real-world patients with chronic pain reduce opioid use while controlling their pain.

Inpatient studies suggest that pain improves with intensive pain rehabilitation and opioid cessation (2). interdisciplinary chronic pain rehabilitation combined with opioid cessation in veterans has been associated with improved indices of psychological and physical function, as well as significantly reduced pain in those who stop opioids during the program (3). However, inpatient and intensive opioid reduction programs are costly and unavailable to most patients. Recently, researchers conducted an outpatient randomized controlled trial comparing an outpatient opioid tapering program to usual care (4). The tapering program consisted of psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant to explore motivation for tapering and learn pain self-management skills.

No studies exist to inform best practice on opioid reduction in primary care or outpatient pain clinics. There is a critical gap in knowledge on how to help community-based (primary care and pain clinic) outpatients with chronic pain actively reduce opioids while controlling pain. This project was intended to inform real-world patient care to specifically help patients with chronic pain taking long term moderate-, high-, and super high-dose opioids reduce their daily use and associated risks. The goal is to understand whether a simple, patient-centered opioid taper conducted with limited resources and no interdisciplinary supportive treatments (e.g., psychology services, physical therapy) could effectively reduce opioid dose without increasing pain.

Methods

Study Design: A prospective observational study of a voluntary patient-centered opioid tapering program. The study was conducted in compliance with the Stanford University's Internal Review Board.

Participants: Adult patients with chronic pain prescribed opioids from a private practice pain clinic in Colorado were invited by their prescribing physician to participate in a voluntary opioid tapering program. Patients who expressed interest were called and invited into the study (note that the study, which involved collecting patient data, is distinct from the taper program. Patients could taper their opioids without agreeing to be studied). Inclusion criteria included adults over the age of 18 years, medically diagnosed chronic pain for at least 6 months, interest in participating in patient-centered opioid tapering, intact cognitive function, an absence of frank psychological disorder, able to speak/read English, able to complete online forms, and not being enrolled in a treatment program for substance use disorder.

Procedure

Patients from a private clinic with chronic pain using daily opioid medications were invited to participate in a voluntary opioid taper program by their physician. Those who agreed to participated were enrolled in the weaning program (taper program) with the physician. After patients provided informed consent, enrolled patients completed a series of online questionnaires that collect data on demographics, psychosocial factors, and physical, emotional, and cognitive function, and opioid medications (type and dose) at baseline and at 4-month follow-up. The opioid taper program was not regulated by the study protocol. It was supervised by the physician, and individually tailored to meet the patient's specific clinical needs. The goal was to reduce opioid consumption at a comfortable pace (individually determined) and target cessation at 4 months from the time they enter the weaning program.

Data Collected:

Demographics included age and gender. Clinical variables included opioid medications, length of time on opioids, pain diagnoses, pain intensity, and marijuana use (yes/no). Opioids were converted to a Morphine Equivalent Daily Dose (MEDD) using standard procedures. MEDDs were calculated for baseline and for the 4 month follow-up time point.

Current Medications Pain Catastrophizing Scale PROMIS Global Health Scale PROMIS Fatigue Scale PROMIS Pain Interference Scale PROMIS Physical Function Scale PROMIS Emotional Distress-Anxiety Scale PROMIS Depression Scale PROMIS Sleep Disturbance Scale PROMIS Sleep Interference PROMIS Pain Behavior Scale PROMIS Social Isolation PROMIS Sleep Related Impairment Scale PROMIS Cognitive Function Scale PROMIS Pain Intensity PROMIS Applied Cog Abilities Marijuana use (yes/no)

Analytic Plan:

Descriptive statistics will include means, medians, ranges, frequencies and percentiles for study variables.

For continuous variables: Welch Two Sample, two-sided t-test without assumption of equal variance will be used.

Polychotomous variables: Pearson's Chi-squared test with Yates' continuity correction. For cells with small numbers, P value will be simulated with 2000 replications.

PRIMARY OUTCOME:

Assuming the primary outcome MEDD will not be normally distributed, Kruskal-Wallis rank sum test will be used to compare MEDD at baseline and 16 weeks.

Pain intensity, our secondary outcome will be assessed similarly.